ALXO
ALX Oncology Holdings Inc.
Biotechnology
Market Cap$100M
5Y Perf.-94.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ALXO vs FATE
Revenue, margins, valuation, and 5-year total return — side by side.
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$280M
5Y Perf.-92.2%
ALXO vs FATE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ALXO | FATE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $100M | $280M |
| Revenue (TTM) | $0.00 | $7M |
| Net Income (TTM) | $-108M | $-136M |
| Operating Margin | — | -22.2% |
| Total Debt | $17M | $78M |
| Cash & Equiv. | $18M | $47M |
ALXO vs FATE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ALXO
FATE
| Stock | Jul 20 | May 26 | Return |
|---|---|---|---|
| ALX Oncology Holdin… (ALXO) | 100 | 5.7 | -94.3% |
| Fate Therapeutics, … (FATE) | 100 | 7.8 | -92.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALXO vs FATE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALXO leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Fate Therapeutics, Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
ALXO
ALX Oncology Holdings Inc.
The Income Pick
ALXO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.44
- EPS growth 31.0%
- Lower volatility, beta 1.44, Low D/E 14.9%, current ratio 7.26x
Best for: income & stability and growth exposure
FATE
Fate Therapeutics, Inc.
The Long-Run Compounder
FATE is the clearest fit if your priority is long-term compounding.
- 40.5% 10Y total return vs ALXO's -93.8%
- -42.7% ROA vs ALXO's -130.6%, ROIC -36.5% vs -71.8%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ALXO | 28.6% revenue growth vs FATE's -51.2% |
| Quality / Margins | ALXO | 5.2% margin vs FATE's -20.5% |
| Stability / Safety | ALXO | Beta 1.44 vs FATE's 2.17, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ALXO | +286.3% vs FATE's +143.0% |
| Efficiency (ROA) | FATE | -42.7% ROA vs ALXO's -130.6%, ROIC -36.5% vs -71.8% |
ALXO vs FATE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
ALXO vs FATE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFATELAGGINGALXO
ALXOALX Oncology Holdings…
0leads
FATEFate Therapeutics, In…
3leads
6 Total Categories
CATEGORYLEADERvs ALXOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FATE1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FATE4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
FATE5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FATE leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
FATE and ALXO operate at a comparable scale, with $7M and $0 in trailing revenue.
| Metric | ALXOALX Oncology Hold… | FATEFate Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $7M |
| EBITDAEarnings before interest/tax | -$111M | -$148M |
| Net IncomeAfter-tax profit | -$108M | -$136M |
| Free Cash FlowCash after capex | -$97M | -$88M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | -22.2% |
| Net MarginNet income ÷ Revenue | — | -20.5% |
| FCF MarginFCF ÷ Revenue | — | -13.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -26.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +29.3% | +38.6% |
FATE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ALXO and FATE each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ALXOALX Oncology Hold… | FATEFate Therapeutics… |
|---|---|---|
| Market CapShares × price | $100M | $280M |
| Enterprise ValueMkt cap + debt − cash | $100M | $312M |
| Trailing P/EPrice ÷ TTM EPS | -0.72x | -2.11x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 42.18x |
| Price / BookPrice ÷ Book value/share | 0.86x | 1.39x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ALXO and FATE each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
FATE leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
FATE delivers a -65.8% return on equity — every $100 of shareholder capital generates $-66 in annual profit, vs $-2 for ALXO. ALXO carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to FATE's 0.38x.
| Metric | ALXOALX Oncology Hold… | FATEFate Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -65.8% |
| ROA (TTM)Return on assets | -130.6% | -42.7% |
| ROICReturn on invested capital | -71.8% | -36.5% |
| ROCEReturn on capital employed | -84.8% | -43.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.15x | 0.38x |
| Net DebtTotal debt minus cash | -$589,000 | $31M |
| Cash & Equiv.Liquid assets | $18M | $47M |
| Total DebtShort + long-term debt | $17M | $78M |
| Interest CoverageEBIT ÷ Interest expense | -64.62x | — |
FATE leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
FATE leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FATE five years ago would be worth $318 today (with dividends reinvested), compared to $288 for ALXO. Over the past 12 months, ALXO leads with a +286.3% total return vs FATE's +143.0%. The 3-year compound annual growth rate (CAGR) favors FATE at -23.6% vs ALXO's -32.7% — a key indicator of consistent wealth creation.
| Metric | ALXOALX Oncology Hold… | FATEFate Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | +62.6% | +145.5% |
| 1-Year ReturnPast 12 months | +286.3% | +143.0% |
| 3-Year ReturnCumulative with dividends | -69.5% | -55.4% |
| 5-Year ReturnCumulative with dividends | -97.1% | -96.8% |
| 10-Year ReturnCumulative with dividends | -93.8% | +40.5% |
| CAGR (3Y)Annualised 3-year return | -32.7% | -23.6% |
FATE leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ALXO and FATE each lead in 1 of 2 comparable metrics.
Risk & Volatility
ALXO is the less volatile stock with a 1.44 beta — it tends to amplify market swings less than FATE's 2.17 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FATE currently trades 98.6% from its 52-week high vs ALXO's 70.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ALXOALX Oncology Hold… | FATEFate Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.44x | 2.17x |
| 52-Week HighHighest price in past year | $2.66 | $2.46 |
| 52-Week LowLowest price in past year | $0.40 | $0.91 |
| % of 52W HighCurrent price vs 52-week peak | +70.3% | +98.6% |
| RSI (14)Momentum oscillator 0–100 | 64.0 | 81.0 |
| Avg Volume (50D)Average daily shares traded | 927K | 1.9M |
Evenly matched — ALXO and FATE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ALXO as "Buy" and FATE as "Buy". Consensus price targets imply 1525.5% upside for FATE (target: $40) vs 113.9% for ALXO (target: $4).
| Metric | ALXOALX Oncology Hold… | FATEFate Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $4.00 | $39.50 |
| # AnalystsCovering analysts | 7 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
FATE leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallFate Therapeutics, Inc. (FATE)Leads 3 of 6 categories
Loading custom metrics...
ALXO vs FATE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ALXO or FATE a better buy right now?
Analysts rate ALX Oncology Holdings Inc.
(ALXO) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ALXO or FATE?
Over the past 5 years, Fate Therapeutics, Inc.
(FATE) delivered a total return of -96. 8%, compared to -97. 1% for ALX Oncology Holdings Inc. (ALXO). Over 10 years, the gap is even starker: FATE returned +40. 5% versus ALXO's -93. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ALXO or FATE?
By beta (market sensitivity over 5 years), ALX Oncology Holdings Inc.
(ALXO) is the lower-risk stock at 1. 44β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 51% more volatile than ALXO relative to the S&P 500. On balance sheet safety, ALX Oncology Holdings Inc. (ALXO) carries a lower debt/equity ratio of 15% versus 38% for Fate Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ALXO or FATE?
On earnings-per-share growth, the picture is similar: ALX Oncology Holdings Inc.
grew EPS 31. 0% year-over-year, compared to 29. 9% for Fate Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ALXO or FATE?
ALX Oncology Holdings Inc.
(ALXO) is the more profitable company, earning 0. 0% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALXO leads at 0. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — ALXO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ALXO or FATE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ALXO or FATE better for a retirement portfolio?
For long-horizon retirement investors, ALX Oncology Holdings Inc.
(ALXO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Fate Therapeutics, Inc. (FATE) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALXO: -93. 8%, FATE: +40. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ALXO and FATE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.